192 related articles for article (PubMed ID: 37934007)
1. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract][Full Text] [Related]
2. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
[TBL] [Abstract][Full Text] [Related]
3. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
5. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
6. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
7. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
8. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
[TBL] [Abstract][Full Text] [Related]
9. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
10. Replacing CAR-T cell resistance with persistence by changing a single residue.
Hsieh EM; Scherer LD; Rouce RH
J Clin Invest; 2020 Jun; 130(6):2806-2808. PubMed ID: 32364534
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
12. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
14. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
[TBL] [Abstract][Full Text] [Related]
15. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.
Liang X; Huang Y; Li D; Yang X; Jiang L; Zhou W; Su J; Chen N; Wang W
Gene Ther; 2023 May; 30(5):411-420. PubMed ID: 33953316
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
17. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A; Liu F; Young RM; June CH; Posey AD
J Clin Invest; 2020 Jun; 130(6):3087-3097. PubMed ID: 32069268
[TBL] [Abstract][Full Text] [Related]
18. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors.
Hirabayashi K; Du H; Xu Y; Shou P; Zhou X; Fucá G; Landoni E; Sun C; Chen Y; Savoldo B; Dotti G
Nat Cancer; 2021 Sep; 2(9):904-918. PubMed ID: 34746799
[TBL] [Abstract][Full Text] [Related]
20. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]